Christina Nickenig

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Hematological Malignancy, Lymphoid Neoplasia, Elderly Patients +7

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Carsten Müller, Niels Murawski, Martin H. J. Wiesen et al. · Blood · 2012 · 233 citations · Full text

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas

Christina Nickenig, Martin Dreyling, Eva Hoster et al. · Cancer · 2006 · 93 citations

Which compartments are involved in Philadelphia‐chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May‐Grünwald‐Giemsa staining and fluorescence <i>in situ</i> hybridization techniques

Torsten Haferlach, Martin Winkemann, Christina Nickenig et al. · British Journal of Haematology · 1997 · 52 citations · Full text

Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20⁺ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL.

Michael Pfreundschuh, Marita Ziepert, Samira Zeynalova et al. · Journal of Clinical Oncology · 2011 · 48 citations

Lymphoid Neoplasia, Clinical Effectiveness, Geriatrics +14